Spotlight: Acucela's Ryo Kubota, Entrepreneur of 2012 Finalist Ryo Kubora performed nearly a thousand eye surgeries and discovered the gene that causes glaucoma, before starting his biotech company, Acucela. His innovation in the field of eye diseases makes him a finalist for Entrepreneur of 2012.

By Jane Porter

Opinions expressed by Entrepreneur contributors are their own.

Spotlight Acucelas Ryo Kubota Entrepreneur of 2012 Finalist

Editor's Note: Each year, we honor a top entrepreneur in our annual Entrepreneur contest. Meet the finalists in the running for Entrepreneur of 2012. Here, a look at Ryo Kubota, founder of Acucela.

Even before Ryo Kubota founded Acucela, a biotechnology company focused on developing therapies for blinding eye diseases, he had an accomplish resume. Early in his career while performing ocular surgery in Keio University in Japan, Kubota discovered the gene that causes glaucoma and performed close to a thousand eye surgeries. Growing increasingly frustrated by the lack of adequate treatment available for devastating eye diseases, Kubota came to the U.S. to expand his research. In 2002, he founded Acucela out of the basement of his home.

In the years since, Acucela has developed oral drugs that have the ability to slow blinding eye diseases like dry age-related macular degeneration, retinopathy of prematurity, Stargardt disease and diabetic retinopathy, which affect millions of people around the world. Today, Acucela is in the second phase of clinical trials for a once-a-day pill that uses a specific enzyme to reduce toxic byproducts that accumulate in the back of the eye, causing glaucoma. "I strongly believe the treatment paradigm in ophthalmology has to be changed," he says. "Instead of injecting things into the eye, we want to do something non-invasively."

Related: 5 Ways Technology Can Help Improve Your Health

By developing less invasive treatments for blinding eye diseases, Kubota hopes to be able to offer oral medication that can cure blinding eye diseases and treat them in their early stages. "The mission that we have is global," says Kubota. "There is no border for disease or drug."
The Seattle-based company now has 80 employees, and in 2011, Acucela made $34.2-million in sales. But despite the strides made in ocular research, Kubota is confident there is still much to be done in terms of discovery in the field. "The ophthalmology space is still relatively untapped in terms of drug development," he says. "Now ophthalmology is the front runner for innovation."

Related: Meet the Finalists for 'Entrepreneur of 2012' and Watch Their Inspirational Stories

Should Ryo Kubota be Entrepreneur of 2012? Vote for him here.

Related: Sentek Global's Eric Basu, Entrepreneur of 2012 Finalist

Related: Adafruit Industries' Limor Fried, Entrepreneur of 2012 Finalist

Related: Fair Trade USA's Paul Rice, Entrepreneur of 2012 Finalist

Related: Justin's Nut Butter's Justin Gold, Entrepreneur of 2012 Finalist

Jane Porter

Writer and editor

Jane Porter is a freelance writer and editor based in Brooklyn, NY. You can find more of her work at Janeroseporter.com

Editor's Pick

Related Topics

Business News

Katy Perry Is Fighting the Founder of 1-800-Flowers for a $15 Million California Mansion He Doesn't Want to Sell Her

The eight-bedroom, 11-bathroom estate sits on nearly nine acres in the Santa Ynez foothills in Montecito.

Growing a Business

Want to Sound Smarter? This Stanford Professor's Simple 3-Point Technique Will Help

With a little structure, you can impress audiences with your ad-libbing all day.

Business News

A Guy Named "Baby Al Capone" Pulled Off a $24 Million Crypto Heist

On this week's episode of "Dirty Money," learn the story of a massive scam pulled off by some gamer buddies who turned very unfriendly when the heat turned up.

Business News

Heinz Announces New Condiment Mixture Inspired By Taylor Swift Dipping Sauce Meme

The multi-Grammy winner was spotted eating a chicken tender with ketchup and "seemingly ranch" while watching Travis Kelce at the Chiefs' game last weekend.